AustriaAustria

Wrist slap for stem cell specialist

12.08.2011

Innsbruck – An Austrian physician has been fined EUR4,500 in a case involving a controversial stem cell therapy for incontinence. In early August, an Innsbruck Regional Court adjudged Hannes Strasser, who developed the method, at fault for false testimony and tampering with evidence. The urologist has promoted his concept at conferences since 2003.
The thera­peutic aim was to strengthen the muscle that keeps the urethra closed, thereby preventing bedwetting. In the disputed method, connective tissue and muscle from the upper arm were initially removed from patients, processed in the laboratory, and then inserted into the urethral sphincter. Nearly 400 patients were treated over the years. The problem is, the doctor apparently did not prove the use and safety of his treatment in clinical studies, nor did he have permission to carry out large Phase III tests. The prosecutor determined that only 21 of the patients were approved by an ethics commission.
A German patient filed suit in 2008 for a refund. In the subsequent case, the court has now considered it proven that the former senior physician made false statements and tampered with the evidence in a civil case. In an interview with Austrian broadcaster ORF, Strasser expressed disappointment at the verdict: “I’m annoyed that I have not been cleared completely.” The ruling, however, is not yet final. The case has been submitted for review to a higher regional court.

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

AustriaAustria

03.11.2010

Austrian vaccine developer Intercell AG (Vienna) has a new Chief Business Officer. At the beginning of October, Staph Leavenworth Bakali quit Intercell’s supervisory board and joined its management board with key responsibilities...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/wrist-slap-for-stem-cell-specialist.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA80.00 CHF6.74%
  • WILEX2.26 EUR1.80%
  • ADDEX4.07 CHF1.75%

FLOP

  • MOLOGEN7.30 EUR-6.41%
  • 4SC1.16 EUR-3.33%
  • EVOLVA1.27 CHF-2.31%

TOP

  • MAGFORCE6.47 EUR19.8%
  • SANTHERA80.00 CHF15.1%
  • LONZA101.50 CHF9.7%

FLOP

  • WILEX2.26 EUR-31.1%
  • MOLOGEN7.30 EUR-22.8%
  • VITA 343.79 EUR-19.9%

TOP

  • SANTHERA80.00 CHF3802.4%
  • CO.DON2.50 EUR228.9%
  • PAION2.41 EUR186.9%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014


Current issue

All issues

Product of the week

Products